tzield
Generic: teplizumab-mzwv
tzield: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PROVENTION BIO, INC. (PBI) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 type 1 diabetes [see Dosage and Administration (2.1) ] . TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D ( 1 ).(PBI)
Frequently asked questions
Who is developing tzield?
tzield is being developed by PROVENTION BIO, INC..
What is tzield's latest FDA decision?
The most recent tracked FDA decision for tzield is Approval for 1 INDICATIONS AND USAGE TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 type 1 diabetes [see Dosage and Administration (2.1) ] . TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D ( 1 )., dated November 17, 2022.
Get deeper analysis on tzield
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis